CHF 4227

Drug Profile

CHF 4227

Alternative Names: CHF 4227.01

Latest Information Update: 30 May 2006

Price : $50

At a glance

  • Originator Chiesi Farmaceutici
  • Class Benzopyrans; Osteoporosis therapies; Piperidines
  • Mechanism of Action Selective estrogen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Phase I Postmenopausal osteoporosis
  • No development reported Breast cancer

Most Recent Events

  • 30 May 2006 No development reported - Preclinical for Breast cancer in Italy (unspecified route)
  • 30 May 2006 This compound is still in active development for Postmenopausal osteoporosis
  • 24 Feb 2004 Phase-I clinical trials in Postmenopausal osteoporosis in Italy (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top